FDA-approved

Heart & blood

Eptifibatide

Evidence

FDA approved

Class

Glycoprotein IIb/IIIa inhibitor

/

Eptifibatide

KEY TAKEAWAY

Eptifibatide is a cyclic peptide that blocks platelet clumping. It is used for acute coronary syndrome and during stent procedures.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A cyclic peptide that blocks platelet aggregation

Approved for

Acute coronary syndrome and percutaneous coronary intervention

Key fact

Reduced death and heart attack in patients with acute coronary syndromes

Route

Intravenous infusion

Evidence strength

FDA approved

What it is

What it is

Eptifibatide, sold as Integrilin, is a small cyclic peptide designed after a protein in snake venom.

How it works

How it works

It blocks the glycoprotein IIb/IIIa receptor on platelets so they cannot stick together to form clots.

Regulatory status

Regulatory status

The FDA approved eptifibatide in 1998 for acute coronary syndrome and angioplasty.

What it is used for

What it is used for

Reducing clot-related events in unstable angina, heart attack and during stenting.

Side effects and risks

Side effects and risks

Bleeding is the most common problem. A drop in platelet count can occur and needs monitoring.

Citations

Citations

PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo